行情

PGEN

PGEN

Precigen Inc
NASDAQ

实时行情|Nasdaq Last Sale

2.810
-0.150
-5.07%
盘后: 2.800 -0.01 -0.36% 19:35 01/21 EST
开盘
3.000
昨收
2.960
最高
3.040
最低
2.800
成交量
181.33万
成交额
--
52周最高
9.89
52周最低
2.800
市值
5.81亿
市盈率(TTM)
-7.6172
分时
5日
1月
3月
1年
5年
Precigen provides pipeline updates for 2022
Precigen (NASDAQ:PGEN) presented pipeline updates at the 40th Annual J.P. Morgan Healthcare Conference. PRGN-3006 UltraCAR-T is being evaluated in a phase 1/1b trial to treat patients with relapsed or refractory AML or
Seekingalpha · 01/12 21:55
Precigen 宣布完成 3 级剂量的淋巴细胞清除队列的注册,在摩根大通健康会议上提供管道更新
PRGN-3006 UltraCAR-T in Acute Myeloid Leukemia (AML) Overview: PRGN-3006 is an investigational multigenic, autologous chimeric antigen receptor T cell (CAR-T) therapy engineered to simultaneously express a CAR
Benzinga · 01/12 21:32
Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 40th Annual J.P. Morgan Healthcare Conf...
PR Newswire · 01/12 21:30
这就是为什么 Precigen, Inc. (PGEN) 可能是底层渔民的绝佳选择
Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates hig...
Zacks · 01/11 15:00
Precigen 将出席第 40 届摩根大通医疗保健年会
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will present a corp...
PR Newswire · 01/05 21:05
3 Synthetic Biology Stocks in Focus With Strong Potential
Zacks.com · 01/04 00:30
Precigen 揭示了血液癌症患者 CAR-T 候选药物的早期数据
Precigen Inc (NASDAQ: PGEN) 
Benzinga · 2021/12/14 13:08
Precigen interim early-stage data on AML therapy shows 50% objective response rate
Precigen's (NASDAQ:PGEN) acute myeloid leukemia candidate PRGN-3006 UltraCAR-T demonstrated an objective response rate of 50% based on six patients. In the lymphodeletion cohort, there were two complete responses at the two
Seekingalpha · 2021/12/13 22:53
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解PGEN最新的财务预测,通过PGEN每股收益,每股净资产,每股现金流等数据分析Precigen Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

20.00%强力推荐
60.00%买入
20.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测PGEN价格均价为12.20,最高价位17.00,最低价为6.00。
最高17.00
均价12.20
最低6.00
现价2.810
EPS
实际EPS
预期EPS
-0.18-0.14-0.09-0.05
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 267
机构持股: 1.42亿
持股比例: 68.59%
总股本: 2.07亿
类型机构数股数
增持
46
177.97万
建仓
35
292.59万
减持
45
835.60万
平仓
11
18.29万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.82%
制药与医学研究
-1.11%
高管信息
Chairman/Executive Director
Randal Kirk
President/Chief Executive Officer
Helen Sabzevari
Chief Financial Officer
Harry Thomasian
Senior Vice President
Jeffrey Perez
Executive Officer
Donald Lehr
Lead Director/Independent Director
Robert Shapiro
Independent Director
Cesar Alvarez
Independent Director
Steven Frank
Independent Director
Vinita Gupta
Independent Director
Fred Hassan
Independent Director
Jeffrey Kindler
Independent Director
Dean Mitchell
Independent Director
James Turley
公告日期
每股分红
除权日期
2015/06/08
Dividend USD 0.162
2015/06/09
PGEN 简况
Precigen Inc(Precigen)是一家合成生物学公司,专注于其发现和临床阶段活动,以推进基因和细胞疗法,以针对免疫肿瘤学,自身免疫性疾病和传染病。该公司正在提供一类基于微生物的生物制药,能够表达和局部递送疾病改善疗法。该公司正在使用精密技术来针对免疫肿瘤学,自身免疫性疾病和传染病中的难治性疾病。该公司还致力于通过开发MiniSwine Yucatan微型猪研究模型和服务来研究威胁生命的人类疾病,并在其基因工程猪中生产细胞和器官用于再生医学应用。该公司的子公司包括PGEN Therapeutics, Inc.、Precigen ActoBio, Inc.、Exemplar Genetics, LLC和Trans Ova Genetics, L.C。

微牛提供Precigen Inc(NASDAQ-PGEN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PGEN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PGEN股票基本功能。